Article

The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood

1] Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, USA. [2] Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Nature Immunology (Impact Factor: 20). 12/2012; 14(2). DOI: 10.1038/ni.2496
Source: PubMed

ABSTRACT

CD4(+)CXCR5(+)Foxp3(+) follicular regulatory T cells (T(FR) cells) inhibit humoral immunity mediated by CD4(+)CXCR5(+)Foxp3(-) follicular helper T cells (T(FH) cells). Although the inhibitory receptor PD-1 is expressed by both cell types, its role in the differentiation of T(FR) cells is unknown. Here we found that mice deficient in PD-1 and its ligand PD-L1 had a greater abundance of T(FR) cells in the lymph nodes and that those T(FR) cells had enhanced suppressive ability. We also found substantial populations of T(FR) cells in mouse blood and demonstrated that T(FR) cells in the blood homed to lymph nodes and potently inhibited T(FH) cells in vivo. T(FR) cells in the blood required signaling via the costimulatory receptors CD28 and ICOS but were inhibited by PD-1 and PD-L1. Our findings demonstrate mechanisms by which the PD-1 pathway regulates antibody production and help reconcile inconsistencies surrounding the role of this pathway in humoral immunity.

Download full-text

Full-text

Available from: Christopher V Carman
  • Source
    • "x-axis represents CD antigen while y-axis represents density of cell binding. tions to limit the proliferation of T cells including T regulatory cells[25]and hence, the balanced expression of this antigen is needed for homeostasis of immune response. Further studies on the upregulated CD antigens found in this study involving larger clinical samples, animal models and in vitro experiments are needed to unlock their roles in gastric cancer immunology, particularly in T cells regulation. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Comprehensive immunophenotyping cluster of differentiation (CD) antigens in gastric adenocarcinoma, specifically between Helicobacter pylori-infected and -uninfected gastric cancer patients by using DotScan(™) antibody microarray has not been conducted. Current immunophenotyping techniques include flow cytometry and immunohistochemistry are limited to the use of few antibodies for parallel examination. We used DotScan(™) antibody microarray consisting 144 CD antibodies to determine the distribution of CD antigens in gastric adenocarcinoma cells and to elucidate the effect of H. pylori infection toward CD antigen expression in gastric cancer. Methods: Mixed leukocytes population derived from gastric adenocarcinoma patients were immunophenotyped using DotScan(™) antibody microarray. AGS cells were infected with H. pylori strains and cells were captured on DotScan(™) slides. Results: Cluster of differentiation antigens involved in perpetuating the tolerance of immune cells to tumor cells was upregulated in gastric adenocarcinoma cells compared to normal cells. CD279 which is essential in T cells apoptosis was found to be upregulated in normal cells. Remarkably, H. pylori-infected gastric cancer patients exhibited upregulated expression of CD27 that important in maintenance of T cells. Infection of cagA+ H. pylori with AGS cells increased CD antigens expression which involved in cancer stem cell while cagA- H. pylori polarized AGS cells to express immune-regulatory CD antigens. Increased CD antigens expression in AGS cells infected with cagA+ H. pylori were also detected in H. pylori-infected gastric cancer patients. Conclusion: This study suggests the tolerance of immune system toward tumor cells in gastric cancer and distinct mechanisms of immune responses exploited by different H. pylori strains.
    Full-text · Article · Jan 2016 · Helicobacter
  • Source
    • "Although PD-1 engagement reduces the number of TFH and TFR cells, this engagement functionally inhibits TFR cells while promoting the ability of TFH cells to secrete pro-GC cytokines such as IL-21. Accordingly, absence of PD-1 results in GC cell death and fewer long-lived plasma cells[34,35]. Other checkpoints under robust investigation include lymphocyte activation gene 3 (LAG-3; CD223), T cell immunoglobulin and mucin- 3 (TIM-3), V-domain Ig suppressor of T-cell activation (VISTA) and Band T-cell lymphocyte attenuator (BTLA), as presented in Fig. 2. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Tumor cells utilize co-inhibitory molecules to avoid host immune destruction. Checkpoint blockade has emerged as a promising approach to treat cancer by restoring T cell effector function and breaking a tumor permissive microenvironment. Patients with hematological malignancies often have immune dysregulation, thus the role of checkpoint blockade in treatment of these neoplasms is particularly intriguing. In early trials, antibodies targeting cytotoxic T lymphocyte antigen 4 (CTLA-4) or the programmed death 1 (PD-1) signaling pathway have displayed significant efficacy with minimal toxicity in patients with relapsed and refractory hematological neoplasms. In this review, we provide evidence of dysregulation of CTLA-4 and PD-1/PD-Ls in the context of several major types of hematological neoplasms and summarize relevant clinical practice points for checkpoint blockade. The preclinical rationale and preliminary clinical data of potential combination approaches designed to optimize checkpoint antagonists are well presented.
    Full-text · Article · Nov 2015 · Blood reviews
  • Source
    • "PP were harvested from unimmunized mice. Serum was isolated from blood using serum separator tubes (BD vacutainer) and NP-specific IgG measured by ELISA as previously described (Sage et al., 2013). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Defective antibody production in aging is broadly attributed to immunosenescence. However, the precise immunological mechanisms remain unclear. Here, we demonstrate an increase in the ratio of inhibitory T follicular regulatory (TFR) cells to stimulatory T follicular helper (TFH) cells in aged mice. Aged TFH and TFR cells are phenotypically distinct from those in young mice, exhibiting increased programmed cell death protein-1 expression but decreased ICOS expression. Aged TFH cells exhibit defective antigen-specific responses, and programmed cell death protein-ligand 1 blockade can partially rescue TFH cell function. In contrast, young and aged TFR cells have similar suppressive capacity on a per-cell basis in vitro and in vivo. Together, these studies reveal mechanisms contributing to defective humoral immunity in aging: an increase in suppressive TFR cells combined with impaired function of aged TFH cells results in reduced T-cell-dependent antibody responses in aged mice. Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.
    Preview · Article · Jul 2015 · Cell Reports
Show more